GlassScriptPhysician profile
William John Bulsiewicz
NPI 1821247693
$6,363.06
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,889 · 2020: $3,274 · 2021: $187 · 2022: $13.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $5,747.01 | 2019-2020 | |
| Abbvie INC. | $341.22 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.21 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.15 | 2019 | |
| Celgene Corporation | $24.65 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $21.18 | 2021 | |
| Daiichi Sankyo INC. | $16.41 | 2019 | |
| Alfasigma USA, INC. | $15.53 | 2021 | |
| Ironwood Pharmaceuticals, INC | $11.82 | 2020 | |
| Allergan, INC. | $11.50 | 2019 | |
| Axonics, INC. | $11.38 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bulsiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.